Abstract
Breast cancer, the most frequent spontaneousmalignancy diagnosed in women in the Western world, isa classical model of hormone dependent malignancy. Thereis substantial evidence that breast cancer risk is associated with prolonged exposure to femalehormones, since early onset of menarche, late menopause,hormone replacement therapy and postmenopausal obesityare associated with greater cancer incidence. Among these hormonal influences a leading roleis attributed to estrogens, either of ovarian orextra-ovarian origin, as supported by the observationsthat breast cancer does not develop in the absence of ovaries, ovariectomy causes regression ofestablished malignancies, and in experimental animalmodels estrogens can induce mammary cancer. Estrogensinduce in rodents a low incidence of mammary tumors after a long latency period, and only in thepresence of an intact pituitary axis, with induction ofpituitary hyperplasia or adenomas andhyperprolactinemia. Chemicals, radiation, viruses andgenomic alterations have all been demonstrated to have a greatertumorigenic potential in rodents. Chemical carcinogensare used to generate the most widely studied rat models;in these models hormones act as promoters or inhibitors of the neoplastic process. Theincidence and type of tumors elicited, however, arestrongly influenced by host factors. The tumorigenicresponse is maximal when the carcinogen is administered to young and virgin intact animals in which themammary gland is undifferentiated and highlyproliferating. The atrophic mammary gland ofhormonally-deprived ovariectomized or hypophysectomizedanimals does not respond to the carcinogenic stimulus.Administration of carcinogen to pregnant, parous orhormonally treated virgin rats, on the other hand, failsto elicit a tumorigenic response, a phenomenon attributed to the higher degree ofdifferentiation of the mammary gland induced by thehormonal stimulation of pregnancy. In women a majorityof breast cancers that are initially hormone dependentare manifested during the postmenopausal period. Estradiolplays a crucial role in their development and evolution.However, it is still unclear whether estrogens arecarcinogenic to the human breast. The apparentcarcinogenicity of estrogens is attributed to receptor-mediatedstimulation of cellular proliferation. Increasedproliferation could result in turn in accumulation ofgenetic damage and stimulation of the synthesis of growth factors that act on the mammaryepithelial cells via an autocrine or paracrine loop.Alternatively estrogens may induce cell proliferationthrough negative feedback by removing the effect of one or several inhibitory factors present in theserum. Multidisciplinary studies are required for theelucidation of the mechanisms responsible for theinitiation of breast cancer. Understanding of suchmechanisms is indispensable for developing a rationalbasis for its prevention and control.
Similar content being viewed by others
References
M. P. Cunningham (1997). Giving life to numbers. CA Cancer J. Clin. 47:3-4.
S. L. Parker, T. Tong, S. Bolden, and P. A. Wingo (1997). Cancer statistics, 1997. CA Cancer J. Clin. 47:5-27.
S. E. King and D. Schottenfeld (1996). The epidemic of breast cancer in the U. S. — Determining the factors. Oncology 10:453-462.
L. A. Gaudette, C. Silberberg, C. A. Altmayer, and R. N. Gao (1996). Trends in breast cancer incidence and mortality. Health Reports. 8:29-40.
A. Seow, S. S. Duffy, M. A. McGee, J. Lee, and H. P. Lee (1996). Breast cancer in Singapore: Trends in incidence 1968-1992. Int. J. Epidemiol. 25,40-45.
G. T. Beatson (1896). On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2:104-107.
C. Huggins (1965). Two principles in endocrine therapy of cancers: Hormone deprival and hormone interference. Cancer Res. 25:1163-1167.
D. F. Easton, D. T. Bishop, D. Ford, and G. P. Crockford (1993). The breast cancer linkage consortium. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am. J. Hum. Genet. 52:678-701.
I. H. Russo and J. Russo (1996). Mammary gland neoplasia in long term rodent studies. Environ. Health Perspect. 104:938-967.
J. L. Kelsey and P. L. Horn-Ross (1993). Breast cancer: Magnitude of the problem and descriptive epidemiology. Epidemiol. Rev. 15:7-16.
E. Petrodidou, E. Syrigou, N. Toupadaki, X. Zavitsanos, and W. Willett (1996). Determinants of age at menarche as early life predictors of breast cancer risk. Int. J. Cancer 68:193-198.
M. Lambe, C.-C. Hsieh, H.-W. Chan, A. Ekbom, D. Trichopoulos, and H. O. Adami (1996). Parity, age at first and last birth, and risk of breast cancer: A population-based study in Sweden. Breast Cancer Res. Treat. 38:305-311.
S. L. Hancock, M. A. Tucker, and R. T. Hoppe (1993). Breast cancer after treatment of Hodgkin' s disease. J. Natl. Cancer Inst. 85:25-31.
J. Russo and I. H. Russo (1994). Toward a physiological approach to breast cancer prevention. Cancer Epidemiol. Biomarkers Prev. 3:353-364.
S. Nandi, R. C. Guzman, and J. Yang (1995). Hormones and mammary carcinogenesis in mice, rats, and humans: A unifying hypothesis. Proc. Natl. Acad. Sci. USA 92:3650-3657.
J. Russo and I. H. Russo (1987). Biological and molecular bases of mammary carcinogenesis. Lab Invest. 57:112-137.
J. Russo, B. A. Gusterson, A. E. Rogers, I. H. Russo, S. R Wellings, and M. J. Van Zwieten (1990). Comparative study of human and rat mammary tumorigenesis. Lab. Invest. 62:1-32.
D. L. McCormick, C. B. Adamowski, A. Fiks, R. C. Moon (1981). Lifetime dose-response relationships for mammary tumor reduction by a single administration of N-methyl-Nnitrosurea. Cancer Res. 41:1690-1694.
C. J. Grubbs, D. R. Farnell, D. L. Hill, and K. C. McDonough (1985). Chemopreventio n of N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17 beta-estradiol and progesterone. J. Natl. Cancer Inst. 74:927-931.
W. P. Bocchinfuso and K. S. Korach (1997). Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J. Mam. Gland Biol. Neoplasia 2:323-334.
R. C. Humphreys, J. Lydon, B. W. O' Malley, and J. M. Rosen (1997). Use of PRKO mice to study the role of progesterone in mammary gland development. J. Mam. Gland Biol. Neoplasia 2:343-353.
D. K. Sinha, J. E. Pazik, and T. L. Dao (1983). Progression of rat mammary development with age and its relationship to carcinogenesis by a chemical carcinogen. Int. J. Cancer 31:321-327.
J. R. Curtis (1982). The role of 7, 12 DMBA and three hormones in 7, 12 DMBA-induced rat mammary cancer: three hypotheses. Med. Hypoth. 9:489-507.
G. R. Cunha, P. Young, Y. K. Hom, P. S. Cooke, J. A. Taylor, and D. B. Lubahn (1997). Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombination experiments. J. Mam. Gland Biol. Neoplasia 2:393-401.
R. G. Edwards, C. M. Howles, and C. Macnamee (1990). Clinical endocrinology of reproduction. In E.-E Baulieu and P. A. Kelly (eds.), Hormones: From Molecules to Disease Chapman and Hall, New York and London, pp. 457-476.
R. B. Dickson, M. Bano, M. D. Johnson, Y. E. Shi, I. Martinez-Lacaci, L. T. Amundadottir, B. Ziff, and J. Kurebayashi (1994). Steroid regulation of growth factors and protooncogenes in the normal and malignant mammary gland. In S. A. Khan and G. M. Stancel (eds.), Protooncogenes and Growth Factors in Steroid Hormone Induced Growth and Differentiation, CRC Press, Boca Raton, Florida, pp. 143-74.
B. K. Vonderhaar (1988). Regulation of development of the normal mammary gland by hormones and growth factors. In M. E. Lippman and R. B. Dickson (eds.), Breast Cancer: Cellular and Molecular Biology, Kluwer, Boston, pp. 251-294.
I. H. Russo, J. Medado, and J. Russo (1989). Endocrine Influ-ences on Mammary Structure and Development. In T. C. Jones, U. Mohr, and R. D. Hunt (eds.), Integument and Mammary Gland of Laboratory Animals, Springer Verlag, Berlin, pp. 252-266.
J. J. Peluso (1992). Morphologic and physiologic features of the ovary. In U. Mohr, D. L. Dungworth, and C. C. Capen (eds.), Pathobiology of the Aging Rat, ILSI Press, Washington, D.C., pp. 337-349.
S. Y. Yung (1988). Inhibins, activins and follistatins: Gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocrine Rev. 9:267-293.
P. A. Kelly, B. I. Posner, T. Tsushima, and H. G. Friessen (1974). Studies of insulin, growth hormone and PRL binding: Ontogenesis, effects of sex and pregnancy Endocrinology 95:532-539
F. Labrie (1990). Glycoprotein hormones: Gonadotropins and thyrotropin. In E.-E Baulieu, and P. A. Kelly (eds.), Hormones: From Molecules to Disease, Chapman and Hall, New York and London, pp. 257-275.
T. K. Woodruff and K. E. Mayo (1990). Regulation of inhibin synthesis in the rat ovary. Ann. Rev. Physiol. 52:807-827.
D. T. Lincoln, F. Sinowatz, E. el-Hifnawi, R. L. Hughes, and M. Waters (1995). Evidence of a direct role for growth hormone (GH) in mammary gland proliferation and lactation. Anatomia, Histologia, Embryologia 24:107-115
J. Russo, Y. F. Hu, X. Ao, C. Grill, and I. H. Russo (1997). Critical appraisal of estrogens as carcinogenic agents in the human breast. Menopause Rev.(submitted).
M. M. King, P. McCoy, and I. H. Russo (1983). Dietary fat may influence DMBA-initiated mammary gland carcinogenesis by modification of mammary gland development. In D. A. Roe (ed.), Current Topics in Nutrition and Disease, Alan R. Liss, Inc. pp. 61-90.
J. Russo, L. K. Tay, and I. H. Russo (1982). Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res. Treat. 2:5-37.
G. Leclercq and J. C. Heuson (1979). Physiological and phar-macological effects of estrogens in breast cancer. Biochem. Biophys. Acta 560:427-455.
A. G. Jabara and A. G. Harcourt (1971). Effect of progesterone, ovariectomy and adrenalectomy on mammary tumors induced by 7,12-dimethylb enzathracene in Sprague-Dawley rats. Pathology 3:209-214.
A. Manni, J. E. Trujillo, and O. H. Pearson (1977). Predominant role of prolactin in stimulating the growth of 7,12-dimethylbe n-za(a)anthracene-induced rat mammary tumors. Cancer Res. 37:1216-1219.
C. W. Welsch (1978). Prolactin and the development and progression of early neoplastic mammary gland lesions. Cancer Res. 38:4054-4058.
C. W. Welsch, C. K. Brown, and M. Goodrich-Smith (1979). Inhibition of mammary tumorigenesis in carcinogen-treat ed Lewis rats by suppression of prolactin secretion. J. Natl. Cancer Inst. 63:1211-1214.
R. Das and B. K. Vonderhaar (1997). Prolactin as a mitogen in mammary cells. J. Mam. Gland Biol. Neoplasia 2:29-39.
A. E. Wakeling (1996). Physiological effects of pure antiestro-gens. In J. R. Pasqualini and B. Katzenellenbogen (eds.), Hor-mone-Dependent Cancer, Marcel Dekker, Inc., New York, pp. 107-118.
R. C. Moon, G. J. Kelloff, C. J. Detrisac, V. E. Steele, C. F. Thomas, and C. C. Sigman (1992). Chemopreventio n of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res. 12:1147-1153.
D. L. McCormick and R. C. Moon (1986). Retinoid-tamoxifen interaction in mammary cancer chemoprevention. Carcinogenesis 7:193-196.
R. L. Stouffer (1990). Corpus luteum function and dysfunction. Clin. Obstet. Gynecol. 33:668-689.
C. K. W. Watts, N. R. C. Wilcken, J. A. Hamilton, K. J. E. Sweeney, A. Musgrove, and R. L. Sutherland (1996). Mecha-nisms of antiestrogen, progestin/antip rogestin, and retinoid inhibition of cell cycle progression in breast cancer cells. In J. R. Pasqualini and B. Katzenellenboge n (eds.), Hormone-Dependent Cancer, Marcel Dekker, Inc., New York, pp. 119-140.
I. H. Russo, P. Gimotty, M. Dupuis, and J. Russo (1989). Effect of the progestagen medroxyprogeste rone acetate on mammary carcinogenesis. Brit. J. Cancer 59:210-216.
C. M. Aldaz, Q. Y. Liao, A. Paladugu, S. Rhem, and H. Wang (1996). Allelotypic and cytogenetic characterization of chemi-cally induced mouse mammary tumors: high frequency of chro-mosome 4 loss of heterozygosity at advanced stages of progression. Mol. Carcinog. 17:126-133.
Y. Lino, T. Ogawa, M. Yoshida, H. Ishikawa, M. Izuo, and H. Takikawa (1990). Effects of sequential and combined endocrine therapies on the growth of 7,12-dimethylbe nz [alpha] anthra-cene-induced rat mammary carcinoma. Jap. J. Clin. Oncol. 20:259-262.
R. D. Wiehle and J. L. Wittliff (1983). Alterations in sex-steroid hormone receptors during mammary gland differentiation in the rat. Comp. Biochem. Physiol. 76:409-417.
G. A. Jahn, M. Edery L. Belair, P. A. Kelly, and J. Dijiane (1991). PRL receptor gene expression in rat mammary gland and liver during pregnancy and lactation. Endocrinology 128:2976-2984.
C. J. Grubbs, M. M. Juliana, D. L. Hill, L. M. Whitaker (1986). Suppression by pregnancy of chemically induced preneoplastic cells of the rat mammary gland. Anticancer Res. 6:2395-2401.
D. R. Ciocca, A. Parente and J. Russo (1982). Endocrinologic milieu and susceptibility of the rat mammary gland to carcino-genesis. Am. J. Pathol. 109:47-56.
I. H. Russo, M. Koszalka, and J. Russo (1991). Comparative study of the influence of pregnancy and hormonal treatment on mammary carcinogenesis. Brit. J. Cancer 64:481-484.
I. H. Russo, M. Koszalka, and J. Russo (1990). Protective effect of chorionic gonadotropin on DMBA-induced mammary carcinogenesis. Brit. J. Cancer 62:243-247.
D. L. McCormick, K. V. Rao, W. D. Johnson, T. A. Bowman-Gram, V. E. Steele, R. A. Lubet, and G. J. Kellof (1996). Exceptional chemopreventive activity of low dose dehydroepi-androsterone in the rat mammary gland. Cancer Res. 56:1724-1726.
H. Ishikawa, Y. Lino, M. Izuo, and H. Takikawa (1986). Com-bined therapies with medroxyprogester one acetate (MPA) in DMBA-induced rat mammary cancer. Gan No Rinsho— Japanese J. Cancer Clinics 32:151-155.
J. Russo and I. H. Russo (1997). Role of Differentiation in the pathogenesis and prevention of breast cancer. Endocrine Related Cancer 4:7-21.
A. M. Soto and C. Sonnenschein (1987). Cell proliferation of estrogen-sensiti ve cells: the case for negative control. Endomonecrine Rev. 48:52-58.
K. K. Huff, C. Knabbe, R. Lindsey, D. Kaufman, D. Bronzert, M. E. Lippman, and R. B. Dickson (1988). Multihormonal regulation of insulin-like growth factor-1-related protein in MCF-7 human breast cancer cells. Mol. Endocrinol. 2:200-208.
B. S. Katzenellenboge n, K. L. Kendra, M. J. Norman, and Y. Berthois (1987). Proliferation, hormonal responsiveness and estrogen receptor content of MCF-7 human breast cancer cells growth in the short-term and long-term absence of estrogens. Cancer Res. 47:4355-4360.
J. Gerdes, U. Schwab, H. Lemke and H. Stein (1983). Production of mouse-monoclon al antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 31:13-20.
G. Calaf, M. E. Alvarado, G. E Bonney, K. K. Amfoh, and J. Russo (1995). Influence of lobular development on breast epithelial cell proliferation and steroid hormone receptor content. Int. J. Oncol. 7:1285-1288.
E. Anderson, R. B. Clarke, and A. Howell (1998). Estrogen responsiveness and control of normal human breast development. J. Mam. Gland Biology Neoplasia 3:23-35.
Rights and permissions
About this article
Cite this article
Russo, I.H., Russo, J. Role of Hormones in Mammary Cancer Initiation and Progression. J Mammary Gland Biol Neoplasia 3, 49–61 (1998). https://doi.org/10.1023/A:1018770218022
Issue Date:
DOI: https://doi.org/10.1023/A:1018770218022